Incidence of malignancies in cardiac allograft recipients – a single-center experience

Sobieszczańska−Małek, Małgorzata; Komuda, Krzysztof; Piotrowska, Małgorzata; Korewicki, J; Małek, Grzegorz; Leszek, Przemysław; Zieliński, Tomasz

doi:10.12659/aot.883843

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to current data, skin cancer is the most frequent malignancy among HTRs. A number of studies have also reported a higher incidence of other cancers, such as lymphoproliferative diseases, lung cancer or uterine and cervical dysplasia 3,4 . This study analyses the data of post-transplant malignancies among HTRs in the CzechRepublic.…”

Section: Introductionmentioning

confidence: 99%

Significantly higher incidence of skin cancer than other malignancies in patients after heart transplantation. A retrospective cohort study in the Czech Republic

Sečníková¹,

Göpfertová²,

Hošková³

et al. 2015

BIOMED PAP

View full text Add to dashboard Cite

Aims.To perform the first study in Czech Republic on heart transplant recipients (HTRs), compare the risks for different types of cancer and provide comprehensive analysis of skin cancer and other types of cancer morbidity from which we would be able to derive an evidence-based skin cancer surveillance program. Materials and Methods. A retrospective cohort study was performed to determine and compare standardized morbidity ratio (SMR) of different types of cancer developed after heart transplantation. We analysed data obtained from medical documentation of 603 HTRs transplanted between 1993 and 2010. Results. 191 incident cases of malignancy occurred in123 HTRs (20.4%). According to expectations, nonmelanoma skin cancer was the most frequent type of malignancy (119 cases) with SMR 7.6 (P < 0.001), followed by lung cancer with SMR 2.7 (P < 0.001). SMR for melanoma was 2.5, P = 0.129. Other types of cancer in HTRs (prostate and kidney cancer) were less frequent (SMR 2.06, P = 0.038 and SMR 2.03, P = 0.122). Conclusion. The risk of malignancy development is significantly higher for HTRs compared to the general population. Squamous cell carcinoma of the skin is the most frequent type of cancer followed by basal cell carcinoma. These findings emphasise the importance of regular skin cancer screening in HTRs.

show abstract

Section: Introductionmentioning

confidence: 99%

Significantly higher incidence of skin cancer than other malignancies in patients after heart transplantation. A retrospective cohort study in the Czech Republic

Sečníková¹,

Göpfertová²,

Hošková³

et al. 2015

BIOMED PAP

View full text Add to dashboard Cite

show abstract

“…The ISHLT 2015 registry reported malignancy developments in about 3.7% of lung transplant recipients who survive to 1 year, 16.6% within 5 years after transplantation, and in 29.1% within 10 years (4). Data on other solid organ recipients are similar (7,8).…”

Section: Discussionmentioning

confidence: 80%

Posttransplant Solid Organ Malignancies in Lung Transplant Recipients: A Single-center Experience and Review of the Literature

Bennett

Fossi

Refini

et al. 2016

Tumori

View full text Add to dashboard Cite

The present study confirmed that de novo malignancies are a major issue in lung transplant patients; in particular, skin and lung cancers demonstrated a higher incidence rate. Oncologic treatment of these patients is complex, requiring close collaboration between the transplant team and oncologist. Strict screening programs are key factors for an early diagnosis and to allow for prompt treatment resulting in a better outcome.

show abstract

“…These are important especially in patients with prior history of nicotine abuse and malignancy, and older age [19]. For aerodigestive malignities, surveillance strategies did not give result with earlier diagnosis, but in cases with higher risk rates physicians should be more suspicious [20].…”

Section: Discussionmentioning

confidence: 99%

Are We Late in the Diagnosis of Malignities Occurring in Solid Organ Transplant Patients? 11 Years’ Experience

et al. 2016

View full text Add to dashboard Cite

Objective: Our aim is to evaluate the frequency and characteristics of cancer in the population of patients with solid organ transplant who are under immunosuppressive medication. In this study we aimed to emphasize the importance of early diagnosis of cancer in solid organ transplant recipients. An aging population began to receive solid organ transplantation and survival times prolonged. But this had a cost and new problems came forward. Especially de novo cancers because of immunosuppressive therapy took notice. Risk of malignancy increases after organ transplantation and cancer incidence was about 2.3-3.1% in these patients including skin cancer, lung cancer, malign lymphoma, cervix cancer, kaposi sarcoma, and hepatobiliary cancer. Materials and Methods:The files of 328 organ transplant recipients followed from January 2004 to April 2015 at Atatürk University Medical Faculty were retrospectively reviewed.Results: Eight patients developed cancer (2.4%). There were six males and two females. Age at cancer diagnosis ranged from 42 to 79 years old with average of 55 years. The interval from solid organ transplantation to cancer diagnosis ranged from 6 months to 30 years. Among the patients, five were renal transplant recipients and two were liver transplant recipients. Four patients had stage IV disease, one patient stage IIIB, and three patients had stage I disease. For none of the patients a diagnosis with screening methods was used for cancer before any complaints of tumor emerged. Conclusion:To diagnose cancer at early stages in solid organ transplant recipients, earlier and detailed cancer screening is very important. The association between diagnosis of cancer at early stages and prolonged overall survival time is well known. Detailed and careful evaluation for occult malignancies in pre-transplantation period is also important. Keywords: Cancer, immunosuppression, screening, transplantation ÖzAmaç: Amacımız solid organ transplantı olan, immunsupresif tedavi altındaki hastalarda gelişen kanser sıklığını ve özelliklerini değerlendirmektir. Bu çalışmada, solid organ transplant alıcıla-rında gelişen kanserlerin erken tanısının önemini vurgulamayı amaçladık. Yaşlanan nüfusla birlikte artan solid organ transplantı ile hayatta kalma süreleri uzamıştır. Fakat bu durum yeni maliyetler getirmiş ve yeni sorunlara neden olmuştur. Özellikle immunsupresif tedavilerin sonucunda de novo kanserler görülme-ye başlamıştır. Organ nakli sonrası kanser riski artar ve en sık cilt kanseri, akciğer kanseri, malign lenfoma, serviks kanseri, kaposi sarkomu ve hepatobilier kanseri içeren bu grupta insidans %2,3-3,1'dir. Sonuç: Solid organ transplant alıcılarında erken evrede kanser tanısı için ayrıntılı ve erken kanser taraması çok önemlidir. Erken tanı ve tedavi ile uzun süreli genel sağkalım arasındaki ilişki iyi bilinmektedir. Nakil öncesi dönemde okült maligniteler için detaylı ve dikkatli bir değerlendirme de önemlidir. Gereç ve

show abstract

Incidence of malignancies in cardiac allograft recipients – a single-center experience

Cited by 6 publications

References 0 publications

Significantly higher incidence of skin cancer than other malignancies in patients after heart transplantation. A retrospective cohort study in the Czech Republic

Significantly higher incidence of skin cancer than other malignancies in patients after heart transplantation. A retrospective cohort study in the Czech Republic

Posttransplant Solid Organ Malignancies in Lung Transplant Recipients: A Single-center Experience and Review of the Literature

Are We Late in the Diagnosis of Malignities Occurring in Solid Organ Transplant Patients? 11 Years’ Experience

Contact Info

Product

Resources

About